La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Kubient a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Kubient..

Kubient (OTC:KBNT) Azioni, Catena delle Opzioni

Kubient

Kubient Inc has developed a cloud-based software platform for real-time trading of digital, programmatic advertising. The platform allows both advertisers and publishers to use machine learning during any programmatic ad space auction.

Kubient Inc

<p>Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.41 by 31.71 percent. This is a 3.85 percent increase over earnings of $0.52 per share from the same period last year.  The company reported quarterly sales of $245.00 million which missed the analyst consensus estimate of $296.25 million by 17.30 percent.  This is a 19.28 percent increase over sales of $205.39 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

News

VNOM

Viper Energy Q1 Adj. EPS $0.54 Beats $0.41 Estimate, Sales $245.00M Miss $296.25M Estimate

<p>Weave Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEAV#NYSE">WEAV</a>) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. This is a 200 percent increase over losses of $(0.01) per share from the same period last year.  The company reported quarterly sales of $55.80 million which beat the analyst consensus estimate of $54.72 million by 1.97 percent.  This is a 18.29 percent increase over sales of $47.17 million the same period last year.</p>


WEAV

Weave Communications Q1 Adj. EPS $0.01, Inline, Sales $55.80M Beat $54.72M Estimate

<p>Upwork (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.26 by 30.77 percent. This is a 54.55 percent increase over earnings of $0.22 per share from the same period last year.  The company reported quarterly sales of $192.71 million which beat the analyst consensus estimate of $188.32 million by 2.33 percent.  This is a 0.93 percent increase over sales of $190.94 million the same period last year.</p>


UPWK

Upwork Q1 Adj. EPS $0.34 Beats $0.26 Estimate, Sales $192.71M Beat $188.32M Estimate

<p>Dorman Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DORM#NASDAQ">DORM</a>) affirms FY2025 GAAP EPS guidance from $7.00-$7.30 to $7.00-$7.30 vs $7.41 analyst estimate..</p>


Guidance

DORM

Dorman Products Affirms FY2025 GAAP EPS Guidance of $7.00-$7.30 vs $7.41 Est

<p>System1 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect System1 to report an <strong>earnings per share</strong> (EPS) of $-0.32.</p>
<p>Investors in System1 are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS beat by $0.04 in the last quarter, leading to a 1.5% increase in the share price on the following day.</p>
<p>Here's a look at System1's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.23</td>
<td>-0.29</td>
<td>-0.42</td>
<td>-0.51</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.19</td>
<td>-0.34</td>
<td>-0.38</td>
<td>-0.45</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>-5.0%</td>
<td>-3.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746475425_0.png" alt="eps graph" /></p>
<h3>System1 Share Price Analysis</h3>
<p>Shares of System1 were trading at $0.4578 as of May 02. Over the last 52-week period, shares are down 76.88%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Observations about System1</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on System1.</p>
<p>System1 has received a total of 1 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $5.0, the consensus suggests a potential 992.18% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of  and System1, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<h3>Summary of Peers Analysis</h3>
<p>In the peer analysis summary, key metrics for  and System1 are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>System1</td>
<td>Buy</td>
<td>-21.35%</td>
<td>$44.70M</td>
<td>-16.60%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>System1 is positioned at the bottom among its peers based on the consensus rating. In terms of revenue growth, System1 is also at the bottom with a negative growth rate. The company's gross profit is at the bottom compared to its peers. Additionally, System1 has the lowest return on equity among its peers.</p>
<h3>All You Need to Know About System1</h3>
<p>System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&amp;O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&amp;O) segment. Geographically, it operates in United States and Other countries.</p>
<h3>Breaking Down System1's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Negative Revenue Trend:</strong> Examining System1's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-21.35%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.</p>
<p><strong>Net Margin:</strong> System1's net margin is impressive, surpassing industry averages. With a net margin of <strong>-18.73%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> System1's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-16.6%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-3.02%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> System1's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>3.43</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/SST/earnings"><strong>To track all earnings releases for System1 visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look at System1's Upcoming Earnings Report

<p>Dorman Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DORM#NASDAQ">DORM</a>) affirms FY2025 Adj EPS guidance from $7.55-$7.85 to $7.55-$7.85 vs $7.69 analyst estimate. Affirms FY2025 sales outlook from $2.07 billion-$2.11 billion to $2.07 billion-$2.11 billion vs $2.10 billion estimate.</p>


Dorman Products Affirms FY2025 Adj EPS Guidance of $7.55-$7.85 vs $7.69 Est; Affirms FY2025 Sales Guidance of $2.07B-$2.11B vs $2.10B Est

<p>Aviat Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVNW#NASDAQ">AVNW</a>) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Aviat Networks to report an <strong>earnings per share</strong> (EPS) of $0.28.</p>
<p>The market awaits Aviat Networks's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.76, which was followed by a 28.22% increase in the share price the next day.</p>
<p>Here's a look at Aviat Networks's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.06</td>
<td>-0.03</td>
<td>0.69</td>
<td>0.51</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.82</td>
<td>-0.87</td>
<td>0.72</td>
<td>0.73</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>28.000000000000004%</td>
<td>-35.0%</td>
<td>-2.0%</td>
<td>-16.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746475414_0.png" alt="eps graph" /></p>
<h3>Aviat Networks Share Price Analysis</h3>
<p>Shares of Aviat Networks were trading at $18.51 as of May 02. Over the last 52-week period, shares are down 38.95%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Insights on Aviat Networks</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Aviat Networks.</p>
<p>Analysts have given Aviat Networks a total of 1 ratings, with the consensus rating being Outperform. The average one-year price target is $30.0, indicating a potential 62.07% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Clearfield, Ribbon Communications and Adtran Holdings, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Clearfield, with an average 1-year price target of $50.0, suggesting a potential 170.12% upside.</li>
<li>Analysts currently favor an Buy trajectory for Ribbon Communications, with an average 1-year price target of $5.83, suggesting a potential 68.5% downside.</li>
<li>Analysts currently favor an Buy trajectory for Adtran Holdings, with an average 1-year price target of $13.33, suggesting a potential 27.98% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Clearfield, Ribbon Communications and Adtran Holdings, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aviat Networks</td>
<td>Outperform</td>
<td>26.15%</td>
<td>$40.89M</td>
<td>1.81%</td>
</tr>
<tr>
<td>Clearfield</td>
<td>Buy</td>
<td>3.64%</td>
<td>$8.18M</td>
<td>-0.70%</td>
</tr>
<tr>
<td>Ribbon Communications</td>
<td>Buy</td>
<td>0.90%</td>
<td>$82.37M</td>
<td>-6.67%</td>
</tr>
<tr>
<td>Adtran Holdings</td>
<td>Buy</td>
<td>7.70%</td>
<td>$91.23M</td>
<td>-24.65%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Aviat Networks ranks first in revenue growth among its peers. It is at the bottom in terms of gross profit. The company is at the top in terms of return on equity.</p>
<h3>Unveiling the Story Behind Aviat Networks</h3>
<p>Aviat Networks Inc is a networking solutions provider. It designs, manufactures and sells wireless networking products, solutions, and services to mobile and fixed operators, private network operators, government agencies, transportation and utility companies, public safety agencies, and broadcast network operators around the world. The company's product categories include point-to-point microwave and millimeter wave radios that are licensed (subject to local frequency regulatory requirements), lightly licensed and license-exempt (operating in license-exempt frequencies), and element and network management software.</p>
<h3>Financial Milestones: Aviat Networks's Journey</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Aviat Networks showcased positive performance, achieving a revenue growth rate of <strong>26.15%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Aviat Networks's net margin is impressive, surpassing industry averages. With a net margin of <strong>3.8%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Aviat Networks's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.81%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Aviat Networks's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.76%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Aviat Networks's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.32</strong>.</p>
<p><a href="https://www.benzinga.com/quote/AVNW/earnings"><strong>To track all earnings releases for Aviat Networks visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


AVNW

Exploring Aviat Networks's Earnings Expectations

<p>AG Mortgage Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-06. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that AG Mortgage Investment will report an <strong>earnings per share</strong> (EPS) of $0.20.</p>
<p>The market awaits AG Mortgage Investment's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>Last quarter the company missed EPS by $0.02, which was followed by a 2.47% drop in the share price the next day.</p>
<p>Here's a look at AG Mortgage Investment's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.20</td>
<td>0.16</td>
<td>0.25</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.18</td>
<td>0.17</td>
<td>0.21</td>
<td>0.21</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>-9.0%</td>
<td>9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746475404_0.png" alt="eps graph" /></p>
<h3>Tracking AG Mortgage Investment's Stock Performance</h3>
<p>Shares of AG Mortgage Investment were trading at $6.65 as of May 02. Over the last 52-week period, shares are down 2.72%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MITT/earnings"><strong>To track all earnings releases for AG Mortgage Investment visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MITT

What's Next: AG Mortgage Investment's Earnings Preview

<p>Heidrick &amp; Struggles Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSII#NASDAQ">HSII</a>) reported quarterly earnings of $0.67 per share which met the analyst consensus estimate. This is unchanged from the same period last year.  The company reported quarterly sales of $286.60 million which beat the analyst consensus estimate of $267.42 million by 7.17 percent.  This is a 8.07 percent increase over sales of $265.20 million the same period last year.</p>


HSII

CORRECTION: Heidrick & Struggles Intl Q1 EPS $0.67, Inline, Sales $283.60M Beat $267.42M Estimate

<p>L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect L.B. Foster to report an <strong>earnings per share</strong> (EPS) of $0.01.</p>
<p>The announcement from L.B. Foster is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.14, leading to a 1.55% drop in the share price on the subsequent day.</p>
<p>Here's a look at L.B. Foster's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.12</td>
<td>0.48</td>
<td>0.46</td>
<td>-0.02</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.02</td>
<td>3.27</td>
<td>0.26</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>6.0%</td>
<td>-3.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746475397_0.png" alt="eps graph" /></p>
<h3>L.B. Foster Share Price Analysis</h3>
<p>Shares of L.B. Foster were trading at $20.59 as of May 02. Over the last 52-week period, shares are down 24.84%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/FSTR/earnings"><strong>To track all earnings releases for L.B. Foster visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


FSTR

Insights Ahead: L.B. Foster's Quarterly Earnings

<p>Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Aligos Therapeutics to report an <strong>earnings per share</strong> (EPS) of $-2.97.</p>
<p>Anticipation surrounds Aligos Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed EPS by $9.41, which was followed by a 0.96% increase in the share price the next day.</p>
<p>Here's a look at Aligos Therapeutics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-3.67</td>
<td>-2.16</td>
<td>-4</td>
<td>-4.75</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-13.08</td>
<td>-3.07</td>
<td>0.75</td>
<td>-5.50</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>6.0%</td>
<td>22.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746475384_0.png" alt="eps graph" /></p>
<h3>Market Performance of Aligos Therapeutics's Stock</h3>
<p>Shares of Aligos Therapeutics were trading at $5.6 as of May 02. Over the last 52-week period, shares are down 74.71%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ALGS/earnings"><strong>To track all earnings releases for Aligos Therapeutics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ALGS

Aligos Therapeutics's Earnings Outlook

<p>Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-06. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Rigel Pharmaceuticals will report an <strong>earnings per share</strong> (EPS) of $0.09.</p>
<p>Investors in Rigel Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS beat by $0.25 in the last quarter, leading to a 8.11% drop in the share price on the following day.</p>
<p>Here's a look at Rigel Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.55</td>
<td>0.06</td>
<td>-0.29</td>
<td>-0.3</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.80</td>
<td>0.70</td>
<td>-0.06</td>
<td>-0.5</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-8.0%</td>
<td>43.0%</td>
<td>6.0%</td>
<td>-17.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746475376_0.png" alt="eps graph" /></p>
<h3>Tracking Rigel Pharmaceuticals's Stock Performance</h3>
<p>Shares of Rigel Pharmaceuticals were trading at $19.36 as of May 02. Over the last 52-week period, shares are up 60.59%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/RIGL/earnings"><strong>To track all earnings releases for Rigel Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


RIGL

A Preview Of Rigel Pharmaceuticals's Earnings

<p>Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.03) by 4.85 percent. This is a 15.29 percent decrease over losses of $(0.85) per share from the same period last year.  The company reported quarterly sales of $20.04 million which beat the analyst consensus estimate of $14.43 million by 38.86 percent.</p>


SNDX

Syndax Pharmaceuticals Q1 EPS $(0.98) Beats $(1.03) Estimate, Sales $20.04M Beat $14.43M Estimate

FANG

Diamondback Energy Issues Shareholder Letter; Lowers FY25 Capital Budget From $3.8B-$4.2B To $3.4B-$3.8B

<p>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Curis to report an <strong>earnings per share</strong> (EPS) of $-1.16.</p>
<p>The announcement from Curis is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS beat by $0.11 in the last quarter, leading to a 30.48% drop in the share price on the following day.</p>
<p>Here's a look at Curis's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.36</td>
<td>-1.91</td>
<td>-1.67</td>
<td>-2.12</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.25</td>
<td>-1.70</td>
<td>-2.03</td>
<td>-2.05</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-30.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746475367_0.png" alt="eps graph" /></p>
<h3>Curis Share Price Analysis</h3>
<p>Shares of Curis were trading at $2.41 as of May 02. Over the last 52-week period, shares are down 85.08%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CRIS/earnings"><strong>To track all earnings releases for Curis visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CRIS

Earnings Outlook For Curis

<p>Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) raises FY2025 sales outlook from $11.75 billion-$12.00 billion to $11.85 billion-$12.00 billion vs $11.97 billion estimate.</p>


VRTX

Vertex Pharmaceuticals Raises FY2025 Sales Guidance from $11.75B-$12.00B to $11.85B-$12.00B vs $11.97B Est

<p><strong>BioAtla</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that BioAtla will report an <strong>earnings per share</strong> (EPS) of $-0.29. </p>
<p>The announcement from BioAtla is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company beat EPS by $0.08, which was followed by a 4.92% drop in the share price the next day.</p>
<p>Here's a look at BioAtla's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.38</td>
<td>-0.36</td>
<td>-0.44</td>
<td>-0.54</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.30</td>
<td>-0.22</td>
<td>-0.44</td>
<td>-0.48</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>-5.0%</td>
<td>0.0%</td>
<td>15.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746475357_0.png" alt="eps graph" /></p>
<h3>Tracking BioAtla's Stock Performance</h3>
<p>Shares of BioAtla were trading at $0.558 as of May 02. Over the last 52-week period, shares are down 83.14%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BCAB/earnings"><strong>To track all earnings releases for BioAtla visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BCAB

A Preview Of BioAtla's Earnings

<p>Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>), a global specialty materials and chemical company, today announced its intent to divest its Micromax<strong>&#xAE;</strong> portfolio of products. The Company's Board and management are confident in the significant value created by a divestment while advancing Celanese's strategic priority of cash generation and deleveraging.</p>
<p>Celanese's Micromax<strong>&#xAE;</strong> business is a leading global supplier of advanced electronic inks and pastes designed for high-performance electronics and is expected to generate over $300 million in 2025 revenue. These materials are used in a variety of applications, including navigation and defense, medical monitoring and advanced circuit board components. Micromax<strong>&#xAE;</strong> products are known for durability, flexibility, and performance in harsh environments. The portfolio includes conductive, resistive, and dielectric thick film inks, as well as Low-Temperature Co-fired Ceramic (LTCC) materials for creating multilayer circuits.</p>
<p>The completion of any separation transaction will be contingent upon various conditions and approvals, including approval by Celanese's board of directors, receipt of requisite regulatory clearances and compliance with applicable U.S. Securities and Exchange Commission requirements. No assurance can be given regarding the form that a transaction may take or the specific terms or timing, or that a sale will in fact occur.</p>
<p><br />&nbsp;</p>


Celanese Intends To Divest Micromax Portfolio Of Product To Advance Cash Generation And Deleveraging Efforts

<p>LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect LifeMD to report an <strong>earnings per share</strong> (EPS) of $0.14.</p>
<p>Investors in LifeMD are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS beat by $0.26, leading to a 30.56% increase in the share price on the subsequent day.</p>
<p>Here's a look at LifeMD's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.05</td>
<td>-0.12</td>
<td>-0.12</td>
<td>-0.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.21</td>
<td>0.09</td>
<td>0.06</td>
<td>0.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>31.0%</td>
<td>14.000000000000002%</td>
<td>-3.0%</td>
<td>-25.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1746475346_0.png" alt="eps graph" /></p>
<h3>Performance of LifeMD Shares</h3>
<p>Shares of LifeMD were trading at $7.25 as of May 02. Over the last 52-week period, shares are down 39.3%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/LFMD/earnings"><strong>To track all earnings releases for LifeMD visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Comments

Kubient

Kubient (KBNT) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO